• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚洲艾滋病疫苗网络(AVAN):扩大在开发 HIV 疫苗方面的区域作用。

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.

机构信息

University of Melbourne, Parkville, Victoria, Australia.

出版信息

PLoS Med. 2010 Sep 21;7(9):e1000331. doi: 10.1371/journal.pmed.1000331.

DOI:10.1371/journal.pmed.1000331
PMID:20877474
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2943436/
Abstract

The HIV/AIDS pandemic continues to spread and an AIDS vaccine is urgently needed. Regional alliances and international collaborations can foster the development and evaluation of the next generation of AIDS vaccine candidates. The importance of coordinating and harmonizing efforts across regional alliances has become abundantly clear. We recently formed the AIDS Vaccine for Asia Network (AVAN) to help facilitate the development of a regional AIDS vaccine strategy that accelerates research and development of an AIDS vaccine through government advocacy, improved coordination, and harmonization of research; develops clinical trial and manufacturing capacity; supports ethical and regulatory frameworks; and ensures community participation.

摘要

艾滋病/艾滋病毒疫情仍在蔓延,急需艾滋病疫苗。区域联盟和国际合作可以促进下一代艾滋病疫苗候选物的开发和评估。协调和统一区域联盟工作的重要性已变得非常明显。我们最近成立了亚洲艾滋病疫苗网络(AVAN),以帮助制定区域艾滋病疫苗战略,通过政府倡导、改进协调和统一研究、开发临床试验和制造能力、支持伦理和监管框架以及确保社区参与,加速艾滋病疫苗的研发。

相似文献

1
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.亚洲艾滋病疫苗网络(AVAN):扩大在开发 HIV 疫苗方面的区域作用。
PLoS Med. 2010 Sep 21;7(9):e1000331. doi: 10.1371/journal.pmed.1000331.
2
Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan).加速艾滋病疫苗的研发:亚洲艾滋病疫苗网络(Avan)
Southeast Asian J Trop Med Public Health. 2011 Sep;42(5):1130-46.
3
Expanding research capacity and accelerating AIDS vaccine development in Asia.扩大亚洲的研究能力并加速艾滋病疫苗的研发。
Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):766-84.
4
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.确定亚洲艾滋病疫苗网络的目标:世界卫生组织-联合国艾滋病规划署/全球艾滋病毒疫苗企业联盟关于扩大亚洲艾滋病疫苗研发能力的区域磋商会报告
Curr Opin HIV AIDS. 2010 Sep;5(5):435-52. doi: 10.1097/COH.0b013e32833c95c1.
5
AIDS vaccine research in Asia: needs and opportunities. Report from a UNAIDS/WHO/NIID meeting Tokyo, 28-30 October 1998.亚洲的艾滋病疫苗研究:需求与机遇。1998年10月28日至30日在东京举行的联合国艾滋病规划署/世界卫生组织/日本国立感染症研究所会议报告
AIDS. 1999 Jul 30;13(11):UNAIDS 1-UNAIDS 13.
6
Strengthening capacity for AIDS vaccine research: analysis of the Pfizer Global Health Fellows program and the International AIDS Vaccine Initiative.加强艾滋病疫苗研究能力:辉瑞全球健康研究员计划和国际艾滋病疫苗倡议分析。
BMC Health Serv Res. 2013 Oct 2;13:378. doi: 10.1186/1472-6963-13-378.
7
Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.构建用于艾滋病疫苗研发的合作网络:艾滋病疫苗免疫接种计划(AVIP)的经验
Springer Semin Immunopathol. 2006 Nov;28(3):289-301. doi: 10.1007/s00281-006-0026-3. Epub 2006 Sep 16.
8
Grappling with global concerns in the search for an HIV vaccine.在寻找艾滋病疫苗的过程中应对全球关注的问题。
J Assoc Nurses AIDS Care. 1999 Jan-Feb;10(1):17-20. doi: 10.1016/S1055-3290(06)60228-8.
9
Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa.非洲艾滋病毒/艾滋病、结核病和疟疾疫苗试验中的趋同伦理问题:世界卫生组织/艾滋病规划署非洲艾滋病疫苗方案的伦理、法律和人权合作中心协商会议报告,2009 年 2 月 10 日至 11 日,南非德班。
BMC Med Ethics. 2010 Mar 9;11:3. doi: 10.1186/1472-6939-11-3.
10
The International AIDS Vaccine Initiative.国际艾滋病疫苗倡议组织
J Int Assoc Physicians AIDS Care. 1997 Nov;3(11):30-4.

引用本文的文献

1
China CDC's HIV/AIDS Vaccine Efforts, from Basic Research to Clinical Studies.中国疾病预防控制中心在艾滋病疫苗方面的努力,从基础研究到临床研究。
China CDC Wkly. 2020 Nov 27;2(48):929-932. doi: 10.46234/ccdcw2020.253.
2
An HIV Vaccine for South-East Asia-Opportunities and Challenges.一种面向东南亚的HIV疫苗——机遇与挑战
Vaccines (Basel). 2013 Aug 14;1(3):348-66. doi: 10.3390/vaccines1030348.
3
Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.

本文引用的文献

1
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.确定亚洲艾滋病疫苗网络的目标:世界卫生组织-联合国艾滋病规划署/全球艾滋病毒疫苗企业联盟关于扩大亚洲艾滋病疫苗研发能力的区域磋商会报告
Curr Opin HIV AIDS. 2010 Sep;5(5):435-52. doi: 10.1097/COH.0b013e32833c95c1.
2
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.一项评估重组1型人类免疫缺陷病毒C亚型修饰安卡拉痘苗病毒候选疫苗在印度志愿者中的安全性和免疫原性的1期研究。
AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.
3
1型人类免疫缺陷病毒CRF07_BC包膜中的三个氨基酸残基调节病毒对人单克隆中和抗体IgG1b12的中和敏感性。
Virol Sin. 2014 Oct;29(5):299-307. doi: 10.1007/s12250-014-3485-z. Epub 2014 Sep 28.
4
HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.HIV-1 Env DNA 疫苗加 EP 递呈的蛋白加强免疫可在体内扩增 B 细胞和 T 细胞应答及中和表型。
PLoS One. 2013 Dec 31;8(12):e84234. doi: 10.1371/journal.pone.0084234. eCollection 2013.
5
The World Health Report 2012 that wasn't.《世界卫生报告 2012 年版:胎死腹中》。
PLoS Med. 2012;9(9):e1001317. doi: 10.1371/journal.pmed.1001317. Epub 2012 Sep 25.
6
The HIV-1 epidemic: low- to middle-income countries.HIV-1 疫情:中低收入国家。
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007187. doi: 10.1101/cshperspect.a007187.
7
Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.新型经过密码子优化的 HIV-1 克鲁弗 2 型(CRF02_AG)和 G 型主要分离株的广谱抗体介导的交叉中和作用和临床前免疫原性。
PLoS One. 2011;6(8):e23233. doi: 10.1371/journal.pone.0023233. Epub 2011 Aug 4.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
4
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.多基因、多进化枝HIV-1改良痘苗病毒安卡拉疫苗的设计与评估
Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.
5
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).通过CD25和CD134(OX40)的共表达刺激揭示外周血中高水平的人抗原特异性CD4 + T细胞。
J Immunol. 2009 Aug 15;183(4):2827-36. doi: 10.4049/jimmunol.0803548. Epub 2009 Jul 27.
6
Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008.对2002年至2008年间在印度孟买JJ医院招募的382名患者的HIV-1逆转录酶序列进行系统发育分析。
AIDS Res Hum Retroviruses. 2009 Jun;25(6):633-5. doi: 10.1089/aid.2008.0261.
7
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.一种具有复制能力的新型痘苗病毒载体MVTT在通过黏膜疫苗接种诱导高水平中和抗体方面优于MVA。
PLoS One. 2009;4(1):e4180. doi: 10.1371/journal.pone.0004180. Epub 2009 Jan 13.
8
Expanding research capacity and accelerating AIDS vaccine development in Asia.扩大亚洲的研究能力并加速艾滋病疫苗的研发。
Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):766-84.
9
African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent.非洲艾滋病疫苗计划,旨在在非洲大陆开展协调一致的合作疫苗研发工作。
PLoS Med. 2008 Dec 2;5(12):e236. doi: 10.1371/journal.pmed.0050236.
10
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.一种细胞介导免疫HIV-1疫苗的疗效评估(STEP研究):一项双盲、随机、安慰剂对照的概念验证试验。
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.